For Pompe I could see value (at least until a better ERT comes along hopefully is say 2015 or so). But given that their chaperone has shown toxicity (granted they'll use much lower doses in combo with ERT) I am skeptical of that compound. They probably need to go back and come up with a new compound for that target but thats the problem of being a "poor" biotech without much capital and even if their Fabry chaperone makes it I don't see it paying the bills.
Market Data 
Markets 
AI
